AVIR
Atea Pharmaceuticals Inc.
$3.15
-$0.04(-1.25%)
62
Overall
60
Value
80
Tech
47
Quality
Market Cap
$258.71M
Volume
232.78K
52W Range
$2.46 - $4.02
Target Price
$6.00
Company Overview
| Mkt Cap | $258.71M | Price | $3.15 |
| Volume | 232.78K | Change | -1.25% |
| P/E Ratio | -1.5 | Open | $3.19 |
| Revenue | -- | Prev Close | $3.19 |
| Net Income | $-168.4M | 52W Range | $2.46 - $4.02 |
| Div Yield | N/A | Target | $6.00 |
| Overall | 62 | Value | 60 |
| Quality | 47 | Technical | 80 |
No chart data available
About Atea Pharmaceuticals Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AVIR | $3.15 | -1.3% | 232.78K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Atea Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW